Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Main Article Content

Joe Merola
Howard Sofen
Diamant Thaci
Carle Paul
Shinichi Imafuku
Subhashis Banerjee
April Armstrong

Keywords

deucravacitinib, JAK inhibitor, phase 3 trial

Abstract

N/A

References

1. Burke JR et al. Sci Transl Med 2019;11:1-16.
2. Wrobleski ST et al. J Med Chem 2019;62:8973-8995.
3. Papp K et al. N Engl J Med 2018;349:1313-1321.
4. Mease PJ et al. Presented at the Annual Scientific Meeting of the American College of Rheumatology; November 5-9, 2020. 5. Armstrong A et al. Presented at the Annual Meeting of the American Academy of Dermatology; April 23-25, 2021.

Most read articles by the same author(s)

<< < 1 2 3 4